초록 ▼

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a lipo

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

대표청구항 ▼

1. A method for treating a non-cystic fibrosis (CF) Mycobacterium avium complex (MAC) lung infection in a patient in need thereof, comprising: administering to the lungs of the patient a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, encapsulated in a

1. A method for treating a non-cystic fibrosis (CF) Mycobacterium avium complex (MAC) lung infection in a patient in need thereof, comprising: administering to the lungs of the patient a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, encapsulated in a plurality of liposomes, wherein the lipid component of the plurality of liposomes consists of an electrically neutral phospholipid and cholesterol,wherein administering to the lungs of the patient comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient once daily in a single dosing session, for an administration period of at least 84 days,and wherein the treating comprises achieving a negative MAC sputum culture in the patient. 2. The method of claim 1, wherein the amikacin or pharmaceutically acceptable salt thereof is amikacin sulfate. 3. The method of claim 1, wherein the plurality of liposomes comprises unilamellar vesicles, multilamellar vesicles, or a mixture thereof. 4. The method of claim 1, wherein the electrically neutral phospholipid is an electrically neutral phosphatidylcholine. 5. The method of claim 4, wherein the electrically neutral phosphatidylcholine is dipalmitoylphosphatidylcholine (DPPC). 6. The method of claim 1, wherein the electrically neutral phospholipid comprises DPPC, and the plurality of liposomes comprise unilamellar vesicles, multilamellar vesicles, or a mixture thereof. 7. The method of claim 6, wherein the volume of the pharmaceutical composition is from about 8 mL to about 10 mL. 8. The method of claim 6, wherein the pharmaceutical composition comprises from about 500 mg to about 650 mg amikacin, or pharmaceutically acceptable salt thereof. 9. The method of claim 6, wherein the pharmaceutical composition is an aqueous dispersion. 10. The method claim 7, wherein the volume of the pharmaceutical composition is about 8 mL. 11. The method of claim 1, wherein during the single dosing session, the aerosolized pharmaceutical composition is administered in less than about 15 minutes. 12. The method of claim 1, wherein during the single dosing session, the aerosolized pharmaceutical composition is administered in about 10 minutes to about 14 minutes. 13. The method of claim 6, wherein about 25% to about 35% of the aerosolized pharmaceutical composition is deposited in the bronchial and alveolar regions of the patient's lungs. 14. The method of claim 6, wherein the patient in need of treatment has bronchiectasis. 15. The method of claim 6, wherein the patient in need of treatment was previously unresponsive to Mycobacterium avium complex (MAC) therapy. 16. The method of claim 6, wherein the patient experiences an improvement in forced expiratory volume in one second (FEV1) for at least 15 days after the administration period ends, as compared to the FEV1 of the patient prior to the administration period. 17. The method of claim 6, wherein the patient experiences an improvement in blood oxygen saturation for at least 15 days after the administration period ends, as compared to the blood oxygen saturation of the patient prior to the administration period. 18. The method of claim 16, wherein the patient's FEV1 is increased at least 5% over the FEV1 of the patient prior to the administration period. 19. The method of claim 16, wherein the patient's FEV1 is increased at least 10% over the FEV1 of the patient prior to the administration period. 20. The method of claim 16, wherein the patient's FEV1 is increased at least 15% over the FEV1 of the patient prior to the administration period. 21. The method of claim 16, wherein the patient's FEV1 is increased by 5% to 50% over the FEV1 prior to the administration period. 22. The method of claim 6, wherein the patient exhibits an increased number of meters walked in the 6 minute walk test (6MWT), as compared to the number of meters walked by the patient prior to undergoing the treatment method. 23. The method of claim 22, wherein the increased number of meters walked in the 6MWT is at least about 5 meters. 24. The method of claim 22, wherein the increased number of meters walked in the 6MWT is from about 5 meters to about 50 meters. 25. The method of claim 22, wherein the increased number of meters walked in the 6MWT is from about 15 meters to about 50 meters. 26. The method of claim 8, wherein the pharmaceutical composition comprises from about 550 mg to about 625 mg amikacin, or pharmaceutically acceptable salt thereof. 27. The method of claim 8, wherein the pharmaceutical composition comprises from about 550 mg to about 600 mg amikacin, or pharmaceutically acceptable salt thereof. 28. The method of claim 1, wherein achieving a negative MAC sputum culture in the patient comprises achieving at least three consecutive negative MAC sputum cultures. 29. The method of claim 1, wherein the administration period is at least about 6 months. 30. The method of claim 28, wherein the administration period is at least about 6 months.